Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.90 |
| ▸ | TERT | O14746 | 12/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4726214 | 0.91 | P2RY12 (0.73) | P2RY12TERTCA12CA9NPY5R | |
| SCHEMBL4726206 | 0.91 | P2RY12 (0.73) | P2RY12TERTCA12CA9NPY5R | |
| SCHEMBL7931748 | 0.85 | P2RY12 (0.82) | P2RY12TERTNPY5RMAOAKDM4E | |
| SCHEMBL6690392 | 0.85 | BRD4 (0.68) | P2RY12TERTCA12CA9NPY5R | |
| SCHEMBL5333828 | 0.80 | P2RY12 (0.72) | P2RY12TERTCA12CA9KDM4E | |
| SCHEMBL11957585 | 0.79 | NPSR1 (0.69) | P2RY12CA12CA9CYP1A2NPSR1 | |
| SCHEMBL19308466 | 0.79 | P2RY12 (0.71) | P2RY12TERTNPY5RKDM4EMTNR1A | |
| SCHEMBL5344753 | 0.78 | P2RY12 (0.70) | P2RY12TERT | |
| SCHEMBL27368087 | 0.77 | KDM4E (0.58) | P2RY12CA12CA9CYP1A2NPSR1 | |
| SCHEMBL5332048 | 0.76 | TERT (1.00) | P2RY12TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015373-A1 | ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS | GE HEALTHCARE UK LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| US-20120015373-A1 | ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS | GE HEALTHCARE UK LIMITED (GB) | 2012-01-19 | — | — | US | disclosed |
| US-8034558-B2 | Incubating dye of given formula with biological material, measuring fluorescence lifetime; lectins/glycoproteins, biotin/streptavidin, DNA/RNA | GE HEALTHCARE UK LIMITED (GB) | 2011-10-11 | — | — | US | disclosed |
| US-8034558-B2 | Incubating dye of given formula with biological material, measuring fluorescence lifetime; lectins/glycoproteins, biotin/streptavidin, DNA/RNA | GE HEALTHCARE UK LIMITED (GB) | 2011-10-11 | — | — | US | disclosed |
| US-20080139788-A1 | ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS | GE HEALTHCARE UK LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
| US-20080139788-A1 | ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS | GE HEALTHCARE UK LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139788-A1 | ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS | ACR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ARSA | P2RY12 1578/4885TERT 2994/4885CA12 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.